SG Americas Securities LLC Sells 56,518 Shares of RxSight, Inc. (NASDAQ:RXST)

SG Americas Securities LLC lessened its position in shares of RxSight, Inc. (NASDAQ:RXST) by 90.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,880 shares of the company’s stock after selling 56,518 shares during the quarter. SG Americas Securities LLC’s holdings in RxSight were worth $291,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of RXST. CWM LLC raised its stake in shares of RxSight by 727.5% during the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after acquiring an additional 371 shares in the last quarter. Quest Partners LLC purchased a new stake in RxSight during the 2nd quarter worth approximately $41,000. Larson Financial Group LLC purchased a new stake in RxSight during the 1st quarter worth approximately $51,000. Amalgamated Bank grew its position in RxSight by 21.3% during the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock worth $71,000 after purchasing an additional 207 shares during the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in RxSight during the 2nd quarter worth approximately $156,000. Institutional investors own 78.78% of the company’s stock.

RxSight Price Performance

RXST stock opened at $50.47 on Monday. The firm’s fifty day simple moving average is $52.12 and its 200-day simple moving average is $53.86. The company has a market capitalization of $1.87 billion, a P/E ratio of -40.06 and a beta of 1.20. RxSight, Inc. has a 12 month low of $20.66 and a 12 month high of $66.54.

RxSight (NASDAQ:RXST) last posted its earnings results on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.06. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. The firm had revenue of $34.89 million during the quarter, compared to analysts’ expectations of $32.33 million. During the same period in the previous year, the business posted ($0.40) EPS. The business’s revenue was up 67.6% compared to the same quarter last year. As a group, sell-side analysts forecast that RxSight, Inc. will post -0.81 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on RXST. Stifel Nicolaus dropped their target price on shares of RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Wells Fargo & Company dropped their target price on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Oppenheimer dropped their target price on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 6th. Needham & Company LLC reissued a “buy” rating and set a $66.00 target price on shares of RxSight in a research report on Friday, September 13th. Finally, BTIG Research upped their price objective on shares of RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a report on Monday, July 15th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $60.14.

Insider Activity at RxSight

In related news, insider Ilya Goldshleger sold 3,100 shares of the business’s stock in a transaction on Friday, September 20th. The shares were sold at an average price of $53.19, for a total value of $164,889.00. Following the completion of the transaction, the insider now directly owns 42,246 shares in the company, valued at $2,247,064.74. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold a total of 40,010 shares of company stock worth $1,905,576 in the last three months. Company insiders own 9.36% of the company’s stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.